Weekly Analysts’ Ratings Changes for Seres Therapeutics (MCRB)

Share on StockTwits

Seres Therapeutics (NASDAQ: MCRB) recently received a number of ratings updates from brokerages and research firms:

  • 5/10/2019 – Seres Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 5/9/2019 – Seres Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
  • 5/8/2019 – Seres Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.75 price target on the stock. According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
  • 5/7/2019 – Seres Therapeutics had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They wrote, “: We reiterate our Overweight rating and $13 price target. We believe Seres is at the forefront of unlocking the potential for microbiome modulation to generate novel methods by which to treat medical conditions. Continuing with the company‚Äôs re-prioritization, Seres announced modifications to the ongoing SER-109 Phase 3 trial to potentially accelerate the top-line data readout. We believe recovery of the stock could be supported by this and the other recent changes that may expedite data demonstrating that microbiome-based therapies have their desired effects.””
  • 5/7/2019 – Seres Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 5/3/2019 – Seres Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 5/3/2019 – Seres Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock. They wrote, “We reiterate our Buy rating with an $8 PT, which was derived by discounting free cash flows for each year by 25%, dividing them by our projected number of shares for each year to account for the effects of share dilution, using a 2% terminal growth rate, and a 72% probability-of-success.””
  • 5/2/2019 – Seres Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $15.00 price target on the stock.
  • 4/30/2019 – Seres Therapeutics is now covered by analysts at Jefferies Financial Group Inc. They set a “hold” rating and a $7.00 price target on the stock.
  • 4/19/2019 – Seres Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 3/27/2019 – Seres Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.

Shares of NASDAQ:MCRB opened at $4.10 on Friday. The company has a market capitalization of $181.23 million, a PE ratio of -1.69 and a beta of 1.80. Seres Therapeutics Inc has a 12 month low of $3.94 and a 12 month high of $9.75.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.12). The firm had revenue of $7.32 million during the quarter, compared to analyst estimates of $8.61 million. Seres Therapeutics had a negative net margin of 301.60% and a negative return on equity of 1,583.95%. Sell-side analysts predict that Seres Therapeutics Inc will post -1.83 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the stock. DekaBank Deutsche Girozentrale increased its position in Seres Therapeutics by 21.5% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 3,500 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in Seres Therapeutics by 945.5% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,339 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 3,924 shares in the last quarter. Bank of New York Mellon Corp increased its position in Seres Therapeutics by 7.6% during the 4th quarter. Bank of New York Mellon Corp now owns 85,364 shares of the biotechnology company’s stock worth $386,000 after purchasing an additional 6,023 shares in the last quarter. State of Wisconsin Investment Board increased its position in Seres Therapeutics by 30.0% during the 1st quarter. State of Wisconsin Investment Board now owns 27,700 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 6,400 shares in the last quarter. Finally, Great West Life Assurance Co. Can acquired a new position in Seres Therapeutics during the 4th quarter worth approximately $30,000. Institutional investors and hedge funds own 81.25% of the company’s stock.

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Read More: Net Income

Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Titan Coin Trading Down 42.2% This Week
Titan Coin Trading Down 42.2% This Week
VanEck Vectors Biotech ETF  and Solar Capital  Head-To-Head Survey
VanEck Vectors Biotech ETF and Solar Capital Head-To-Head Survey
Voise  Price Down 6.8% This Week
Voise Price Down 6.8% This Week
Edgewell Personal Care Co  Receives $44.50 Consensus PT from Analysts
Edgewell Personal Care Co Receives $44.50 Consensus PT from Analysts
WeAreSatoshi  Price Down 9.8% Over Last Week
WeAreSatoshi Price Down 9.8% Over Last Week
GRIFOLS S A/S  Receives Average Rating of “Hold” from Analysts
GRIFOLS S A/S Receives Average Rating of “Hold” from Analysts


© 2006-2019 Ticker Report